Abdom Radiol (NY)

1. GUO E, Chen L, Xu L, Zhang D, et al
   Optimizing bladder magnetic resonance imaging: accelerating scan time and improving image quality through deep learning.
   Abdom Radiol (NY). 2025;50:4772-4782.
   

   >> Share

   
   

   
   Acad Radiol

2. DU Y, Sui Y, Tao Y, Cao J, et al
   Comprehensive Assessment of Tumor Stromal Heterogeneity in Bladder Cancer by Deep Learning and Habitat Radiomics.
   Acad Radiol. 2025 Sep 22:S1076-6332(25)00799-8. doi: 10.1016/j.acra.2025.
   

   >> Share

   
   

   
   Anal Chem

3. ZHANG T, Zhang H, Qi J, Jiang S, et al
   Hollow Dodecahedral Nanocages for Reliable Multi-Level Differentiation of Urological Cancers through Non-Invasive Metabolic Fingerprinting.
   Anal Chem. 2025;97:20622-20631.
   

   >> Share

   
   

   
   Angew Chem Int Ed Engl

4. CHENG Y, Zhou K, Chen Y, Mei Y, et al
   Concurrent Ferroptosis and Pyroptosis Induced by a Dual-Organelle-Targeted Type I/II AIE Photosensitizer for Bladder Cancer Immunotherapy.
   Angew Chem Int Ed Engl. 2025 Sep 18:e202509783. doi: 10.1002/anie.202509783.
   

   >> Share

   
   

   
   Ann Oncol

5. POWLES TB, Van der Heijden MS, Loriot Y, Bedke J, et al
   Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial.
   Ann Oncol. 2025;36:1212-1219.
   

   >> Share

   
   

   
   BJU Int

6. KALEN E, Ginstman C, Liedberg F, Hagberg O, et al
   Incidence and risk factors for postoperative vaginal events following radical cystectomy for bladder cancer: a nationwide population-based study.
   BJU Int. 2025 Sep 20. doi: 10.1111/bju.70004.
   

   >> Share

   
   

   
   Bladder Cancer

7. BUKAVINA L, Isali I, Parekh S, Psutka S, et al
   Genetic susceptibility and environmental risk factors in bladder cancer: Evidence from the UK biobank.
   Bladder Cancer. 2025;11:23523735251370863.
   

   >> Share

   
   

   
   Cancer Res Treat

8. YING W, Li D, Feng N, Wei W, et al
   LncRNA DGUOK-AS1 Promotes Bladder Cancer Progression by Enhancing EFTUD2 Stability.
   Cancer Res Treat. 2025 Sep 18. doi: 10.4143/crt.2025.
   

   >> Share

   
   

   
   Clin Genitourin Cancer

9. JUHASZ D, Csizmarik A, Varadi M, Bacso D, et al
   Lymphovascular Invasion is Predictive for Adjuvant Platinum Therapy Benefit in Urothelial Bladder Cancer.
   Clin Genitourin Cancer. 2025 Sep 1:102421. doi: 10.1016/j.clgc.2025.102421.
   

   >> Share

   
   

   
   Crit Rev Oncol Hematol

10. TATAR AC, Loghin A, Nechifor-Boila A, Raicea A, et al
    IHC-based molecular classification in muscle-invasive urothelial bladder carcinoma: Prognostic and predictive value toward a clinically applicable IHC marker panel - A systematic review.
    Crit Rev Oncol Hematol. 2025;214:104868.
    

    >> Share

    
    

    
    Cureus

11. YONG ZONG AT, Yap WK
    Global Research Trends in Bladder Cancer Biomarkers: A Bibliometric Analysis.
    Cureus. 2025;17:e90724.
    

    >> Share

    
    

    
    Curr Opin Urol

12. WONG CH, Leung DK, Gontero P, Teoh JY, et al
    Gene-mediated therapy for BCG-unresponsive nonmuscle-invasive bladder cancer: mechanisms, clinical evidence, and practical implementation.
    Curr Opin Urol. 2025 Sep 19. doi: 10.1097/MOU.0000000000001345.
    

    >> Share

    
    
13. GABRIEL PE, Horowitz A, Sfakianos JP, Xylinas E, et al
    Targeted therapies for Bacillus Calmette-Guerin unresponsive nonmuscle-invasive bladder cancer: a narrative review.
    Curr Opin Urol. 2025 Sep 19. doi: 10.1097/MOU.0000000000001343.
    

    >> Share

    
    

    
    Eur Urol

14. DING D, Qian L, Jin D, Zhou X, et al
    Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study.
    Eur Urol. 2025 Sep 19:S0302-2838(25)00493-2. doi: 10.1016/j.eururo.2025.
    

    >> Share

    
    
15. ZUGMAN M, Carneiro A, Maluf FC
    Challenging the Guidelines: Rethinking Neoadjuvant Therapy for Histologic Subtypes of Bladder Cancer.
    Eur Urol. 2025 Sep 17:S0302-2838(25)00510-X. doi: 10.1016/j.eururo.2025.
    

    >> Share

    
    
16. HECK MM, Lehmann J, Amiel T, Rubben H, et al
    Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy.
    Eur Urol. 2025 Sep 17:S0302-2838(25)00489-0. doi: 10.1016/j.eururo.2025.
    

    >> Share

    
    

    
    Eur Urol Oncol

17. CAO M, Yang G, Zhao T, Zhang L, et al
    Development and Validation of the UriMee Model: A Methylation-based Diagnostic Tool for Early Diagnosis of Urothelial Carcinoma.
    Eur Urol Oncol. 2025;8:899-908.
    

    >> Share

    
    
18. JAIN RK, Swami U, Bilen MA, Gebrael G, et al
    Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial.
    Eur Urol Oncol. 2025;8:952-960.
    

    >> Share

    
    
19. MATSUBARA N, Loriot Y, Banek S, Valderrama BP, et al
    Fibroblast Growth Factor Receptor Alteration Testing for >3600 Patients with Locally Advanced/Metastatic Urothelial Cancer and Non-muscle-invasive Bladder Cancer: An Analysis of the Global ANNAR Biomarker Study.
    Eur Urol Oncol. 2025 Sep 22:S2588-9311(25)00201.
    

    >> Share

    
    
20. GRIVAS P, Aragon-Ching JB, Bellmunt J, Loriot Y, et al
    Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial.
    Eur Urol Oncol. 2025;8:941-951.
    

    >> Share

    
    

    
    Eur Urol Open Sci

21. LIEDBERG F, Hagberg O, Beijert IJ, Aljabery F, et al
    Applicability of the European Association of Urology 2021 Prognostic Model for Non-muscle-invasive Bladder Cancer in a Swedish Population-based Cohort.
    Eur Urol Open Sci. 2025;80:33-37.
    

    >> Share

    
    

    
    Expert Rev Mol Diagn

22. LIN N, Zhou Y, Li Y, Lin L, et al
    Circulating tumor DNA and Urinary tumor DNA: useful biomarkers for bladder cancer detection.
    Expert Rev Mol Diagn. 2025 Sep 22. doi: 10.1080/14737159.2025.2565273.
    

    >> Share

    
    

    
    Front Cell Dev Biol

23. RUIZ-LORENTE I, Gimeno L, Lopez-Abad A, Lopez Cubillana P, et al
    Interplay of KIR2DL5, nitric oxide, and tobacco smoking in predisposition to bladder cancer.
    Front Cell Dev Biol. 2025;13:1632101.
    

    >> Share

    
    

    
    Future Sci OA

24. ZHANG H, Tang K, Chen Y, Chen G, et al
    Downregulated of CTGF reveals mechanism, remodels immune microenvironment, modulates drug sensitivity in bladder cancer.
    Future Sci OA. 2025;11:2560297.
    

    >> Share

    
    

    
    Gene

25. BOILLAT S, Goasmat V, Derre L, Domingos-Pereira S, et al
    Role of myeloid-derived suppressor cells in bladder cancer and targeted therapeutic strategies.
    Gene. 2025 Sep 20:149772. doi: 10.1016/j.gene.2025.149772.
    

    >> Share

    
    

    
    Hum Mutat

26. SUN Y, Yi X, Zhou C, Huang Y, et al
    PAQR4: A Critical Senescence-Related Gene Influencing Immune Evasion and Metastasis in Bladder Urothelial Carcinoma.
    Hum Mutat. 2025;2025:2227219.
    

    >> Share

    
    

    
    Int J Urol

27. 
    RETRACTION: Astrocyte Elevated Gene-1 Promotes Invasion and Epithelial-Mesenchymal Transition in Bladder Cancer Cells Through Activation of Signal Transducer and Activator of Transcription 3.
    Int J Urol. 2025 Sep 20. doi: 10.1111/iju.70224.
    

    >> Share

    
    

    
    J Am Soc Cytopathol

28. VAN TASSEL E, Howell J, Walls K, Crabtree W, et al
    Outcome of atypical urothelial cells (AUC) in patients without prior history of urothelial carcinoma.
    J Am Soc Cytopathol. 2025;14:334-340.
    

    >> Share

    
    

    
    J Control Release

29. MIAO Z, Xu A, Shen G, Tang S, et al
    Fluorinated albumin nanocages dually target CAFs and tumor cells to potentiate bladder cancer chemoimmunotherapy.
    J Control Release. 2025;387:114246.
    

    >> Share

    
    

    
    Oncologist

30. JANG A, Tripathi N, Lanka SM, Kumar HLS, et al
    Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure?
    Oncologist. 2025;30:oyaf259.
    

    >> Share

    
    

    
    PLoS One

31. KATO T, Okauchi N, Motegi T, Sakurai M, et al
    Lactic acid regulates antitumor immunity in canine invasive urothelial carcinoma.
    PLoS One. 2025;20:e0332825.
    

    >> Share

    
    

    
    Radiologia (Engl Ed)

32. ETXANO J, Lopez-Maseda A
    Clinical applications of bladder magnetic resonance imaging: Beyond the VI-RADS(R) classification.
    Radiologia (Engl Ed). 2025;67:101668.
    

    >> Share

    
    

    
    Target Oncol

33. GRIVAS P, Moon HH
    A Podcast on Real-World Evidence with Avelumab First-Line Maintenance and Treatment Sequencing in Locally Advanced or Metastatic Urothelial Carcinoma.
    Target Oncol. 2025;20:743-754.
    

    >> Share

    
    

    
    Tissue Cell

34. ALONSO JCC, Goncalves JM, de Arruda Camargo GC, de Oliveira G, et al
    Dual molecular axis of resistance and immunoresponsiveness to BCG in pT1 non-muscle invasive bladder cancer: Insights from HER-2, SERBP1, HABP4, and IFN-gamma profiling.
    Tissue Cell. 2025;98:103137.
    

    >> Share

    
    

    
    Urol Oncol

35. DEL GIUDICE F, Santarelli V, Laszkiewicz J, Li S, et al
    The influence of immunocompromised status on recurrence and progression free survival among nonmuscle invasive bladder cancers (NMIBCs) undergoing transurethral resection of bladder tumor (TURBT) and adjuvant intravesical bacillus Calmette Guerin (BCG
    Urol Oncol. 2025 Sep 19:S1078-1439(25)00254.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share